[go: up one dir, main page]

HUE070078T2 - Nem-peptid oxitocinreceptor-agonisták - Google Patents

Nem-peptid oxitocinreceptor-agonisták

Info

Publication number
HUE070078T2
HUE070078T2 HUE17880082A HUE17880082A HUE070078T2 HU E070078 T2 HUE070078 T2 HU E070078T2 HU E17880082 A HUE17880082 A HU E17880082A HU E17880082 A HUE17880082 A HU E17880082A HU E070078 T2 HUE070078 T2 HU E070078T2
Authority
HU
Hungary
Prior art keywords
receptor agonists
oxytocin receptor
peptide oxytocin
peptide
agonists
Prior art date
Application number
HUE17880082A
Other languages
English (en)
Inventor
Michael Kassiou
William Jorgensen
Eryn Werry
Tristan Reekie
Michael Bowen
Iain Mcgregor
Original Assignee
Kinoxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905126A external-priority patent/AU2016905126A0/en
Application filed by Kinoxis Therapeutics Pty Ltd filed Critical Kinoxis Therapeutics Pty Ltd
Publication of HUE070078T2 publication Critical patent/HUE070078T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
HUE17880082A 2016-12-12 2017-12-12 Nem-peptid oxitocinreceptor-agonisták HUE070078T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2016905126A AU2016905126A0 (en) 2016-12-12 Non-peptide oxytocin receptor agonists

Publications (1)

Publication Number Publication Date
HUE070078T2 true HUE070078T2 (hu) 2025-05-28

Family

ID=62557695

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17880082A HUE070078T2 (hu) 2016-12-12 2017-12-12 Nem-peptid oxitocinreceptor-agonisták

Country Status (19)

Country Link
US (2) US11491165B2 (hu)
EP (2) EP4494705A3 (hu)
JP (3) JP7089649B2 (hu)
KR (1) KR102561721B1 (hu)
CN (1) CN110248944A (hu)
AU (1) AU2017377653B2 (hu)
BR (1) BR112019012049A2 (hu)
CA (1) CA3046809A1 (hu)
DK (1) DK3551631T3 (hu)
ES (1) ES3001195T3 (hu)
FI (1) FI3551631T3 (hu)
HU (1) HUE070078T2 (hu)
IL (1) IL267276B2 (hu)
MX (1) MX2019006942A (hu)
PL (1) PL3551631T3 (hu)
PT (1) PT3551631T (hu)
RU (1) RU2019120162A (hu)
SI (1) SI3551631T1 (hu)
WO (1) WO2018107216A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102857A1 (en) * 2018-11-23 2020-05-28 The University Of Sydney Methods for management of weight
EP4025221A4 (en) * 2019-09-06 2024-01-03 Kinoxis Therapeutics Pty Ltd TREATMENT OF OPIOID WITHDRAWAL
CA3154131A1 (en) 2019-09-13 2021-03-18 Origenis Gmbh 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease
AU2021401996A1 (en) * 2020-12-14 2023-07-13 Kinoxis Therapeutics Pty Ltd Oxytocin receptor modulators
EP4308127A4 (en) * 2021-03-18 2025-01-01 Kinoxis Therapeutics Pty Ltd TREATMENT PROCEDURES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770762A (en) * 1972-08-29 1973-11-06 Parke Davis & Co Diazepine compounds and methods for their production
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
US7342112B2 (en) * 2003-07-01 2008-03-11 Ppg Industries Ohio, Inc. Photochromic compounds
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
JP2008515939A (ja) * 2004-10-13 2008-05-15 エフ.ホフマン−ラ ロシュ アーゲー Cdk2及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な2置換ピラゾロベンゾジアゼピン
CN101203516A (zh) * 2005-04-05 2008-06-18 法马科皮亚公司 用于免疫抑制的嘌呤及咪唑并吡啶衍生物
WO2007050353A2 (en) * 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
WO2008103367A2 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, proapoptotic compounds discovered by same
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
EP3226689B1 (en) * 2014-12-05 2020-01-15 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
ES2932194T3 (es) * 2015-07-06 2023-01-16 Kinoxis Therapeutics Pty Ltd Compuestos terapéuticos y composiciones para el tratamiento de trastornos sociales y trastornos por uso de sustancias

Also Published As

Publication number Publication date
FI3551631T3 (fi) 2025-01-16
AU2017377653B2 (en) 2022-04-21
JP2022097655A (ja) 2022-06-30
EP3551631B9 (en) 2025-02-26
BR112019012049A2 (pt) 2019-11-12
EP3551631B1 (en) 2024-11-13
SI3551631T1 (sl) 2025-03-31
WO2018107216A1 (en) 2018-06-21
NZ754890A (en) 2025-03-28
JP2024107136A (ja) 2024-08-08
EP3551631A4 (en) 2020-07-15
JP2020500924A (ja) 2020-01-16
MX2019006942A (es) 2019-10-21
RU2019120162A (ru) 2021-01-12
US11491165B2 (en) 2022-11-08
PL3551631T3 (pl) 2025-03-24
EP4494705A3 (en) 2025-04-02
CA3046809A1 (en) 2018-06-21
EP3551631A1 (en) 2019-10-16
EP4494705A2 (en) 2025-01-22
ES3001195T3 (es) 2025-03-04
IL267276B1 (en) 2024-05-01
IL267276A (en) 2019-08-29
JP7089649B2 (ja) 2022-06-23
RU2019120162A3 (hu) 2021-01-28
DK3551631T3 (en) 2025-02-17
PT3551631T (pt) 2024-12-10
KR102561721B1 (ko) 2023-07-28
US20200000823A1 (en) 2020-01-02
CN110248944A (zh) 2019-09-17
US20230330103A1 (en) 2023-10-19
IL267276B2 (en) 2024-09-01
KR20190091534A (ko) 2019-08-06
AU2017377653A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
IL259531B (en) Test facility
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
AP2016009445A0 (en) Muscarinic receptor agonists
GB201402550D0 (en) Assay device
GB201602771D0 (en) Support evaluation device
IL248707A0 (en) Integral dual gimbal device
IL267276A (en) Non-peptide oxytocin receptor agonists
GB201403820D0 (en) Assay
GB201514730D0 (en) Assay device
IL248625A0 (en) Peptides as oxytocin agonists
IL248553A0 (en) Peptides as oxytocin agonists
GB201619637D0 (en) C3a receptor agonists
GB201602867D0 (en) Devcice holder
GB201415343D0 (en) Blomarker assay
GB201514712D0 (en) Assay device
GB2531332B (en) Location identification
GB201419072D0 (en) Assay
AU2016905126A0 (en) Non-peptide oxytocin receptor agonists
GB201514706D0 (en) Assay device
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
GB201515276D0 (en) Id Holder
GB201400386D0 (en) Agonists
PH32014000746S1 (en) Shoulder support